218 related articles for article (PubMed ID: 30317526)
21. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.
Ban M; Viculin J; Tomic S; Capkun V; Strikic A; Mise BP; Utrobicic I; Vrdoljak E
Neoplasma; 2016; 63(5):761-7. PubMed ID: 27468880
[TBL] [Abstract][Full Text] [Related]
22. Expression of activated type I receptor tyrosine kinases in early breast cancer.
Spears M; Pederson HC; Lyttle N; Gray C; Quintayo MA; Brogan L; J Thomas JS; Kerr GR; Jack WJ; Kunkler IH; Cameron DA; Chetty U; Bartlett JM
Breast Cancer Res Treat; 2012 Jul; 134(2):701-8. PubMed ID: 22562124
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
24. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
[TBL] [Abstract][Full Text] [Related]
25. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hirakawa A; Ono M; Kouno T; Katsumata N; Ando M; Tamura K; Hasegawa T; Kinoshita T; Fujiwara Y
J Surg Oncol; 2010 Mar; 101(3):222-7. PubMed ID: 20087905
[TBL] [Abstract][Full Text] [Related]
27. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
[TBL] [Abstract][Full Text] [Related]
28. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
29. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
30. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.
Furrer D; Jacob S; Michaud A; Provencher L; Lemieux J; Diorio C
Clin Breast Cancer; 2018 Aug; 18(4):e687-e694. PubMed ID: 29275864
[TBL] [Abstract][Full Text] [Related]
31. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
32. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA
Br J Cancer; 2018 Feb; 118(3):441-447. PubMed ID: 29136405
[TBL] [Abstract][Full Text] [Related]
33. Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.
Abduyev Z; Altundag K
J BUON; 2019; 24(5):2208. PubMed ID: 31786900
[No Abstract] [Full Text] [Related]
34. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.
Maadi H; Nami B; Tong J; Li G; Wang Z
BMC Cancer; 2018 Mar; 18(1):238. PubMed ID: 29490608
[TBL] [Abstract][Full Text] [Related]
35. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA
Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
[TBL] [Abstract][Full Text] [Related]
37. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
38. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
39. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
40. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
Chen L; Zhou W; Hu X; Yi M; Ye C; Yao G
Cancer Treat Rev; 2019 May; 75():12-19. PubMed ID: 30856373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
